Henry Schein (NASDAQ:HSIC) had its price target lifted by equities researchers at Piper Sandler from $79.00 to $89.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price objective would indicate a potential upside of 10.71% from the company’s previous close.
Several other brokerages also recently issued reports on HSIC. Robert W. Baird raised Henry Schein from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $70.00 to $79.00 in a research note on Monday, January 4th. Barrington Research raised their price target on Henry Schein from $72.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, February 18th. Zacks Investment Research downgraded Henry Schein from a “buy” rating to a “hold” rating and set a $77.00 price target for the company. in a research note on Friday. Finally, TheStreet lowered Henry Schein from a “b” rating to a “c+” rating in a report on Thursday, February 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Henry Schein has a consensus rating of “Hold” and a consensus price target of $72.50.
Shares of NASDAQ HSIC traded up $6.38 during mid-day trading on Tuesday, hitting $80.39. 77,289 shares of the company traded hands, compared to its average volume of 1,024,021. Henry Schein has a 1 year low of $49.83 and a 1 year high of $74.89. The stock has a market capitalization of $11.44 billion, a price-to-earnings ratio of 19.67, a PEG ratio of 3.12 and a beta of 0.86. The company has a quick ratio of 0.92, a current ratio of 1.49 and a debt-to-equity ratio of 0.14. The business has a 50 day moving average of $69.70 and a two-hundred day moving average of $67.35.
In other Henry Schein news, Director Deborah Derby bought 760 shares of the stock in a transaction on Wednesday, February 24th. The shares were purchased at an average price of $66.22 per share, with a total value of $50,327.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.05% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. WD Rutherford LLC acquired a new stake in shares of Henry Schein during the 4th quarter worth approximately $62,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of Henry Schein during the 1st quarter worth approximately $83,000. First Horizon Advisors Inc. grew its holdings in shares of Henry Schein by 1,087.4% during the 4th quarter. First Horizon Advisors Inc. now owns 1,318 shares of the company’s stock worth $88,000 after purchasing an additional 1,207 shares in the last quarter. Vantage Consulting Group Inc acquired a new stake in shares of Henry Schein during the 4th quarter worth approximately $116,000. Finally, Montag A & Associates Inc. acquired a new stake in shares of Henry Schein during the 4th quarter worth approximately $134,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.
Henry Schein Company Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Featured Story: Investing in Blue-Chip Stocks
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.